Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Inhibikase Therapeutics (IKT) Ownership Overview
9.88% Insiders
4.63% Mutual Funds
60.31% Other Institutional Investors
6.02% ETFs
19.17% Public Companies and
Individual Investors
The ownership structure of Inhibikase Therapeutics (IKT) stock is a mix of institutional, retail, and individual investors. Approximately 70.95% of the company’s stock is owned by Institutional Investors, 9.88% is owned by Insiders, and 19.17% is owned by Public Companies and Individual Investors.
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
Jun 30, 2025 | xxxxxxxxxxxxx | $5144638 | |
Jun 30, 2025 | xxxxxxxxxxxxx | $10592971 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 6,125,000 | Institution | 8.22% | 9,616,250 | |
| 5,432,293 | Institution | 7.29% | 8,528,700 | |
| 5,335,433 | Insider | 7.16% | 8,376,630 | |
| 2,933,673 | Institution | 3.94% | 4,605,867 | |
| 2,760,750 | Institution | 3.70% | 4,334,378 | |
| 2,638,276 | Institution | 3.54% | 4,142,093 | |
| 1,751,687 | Institution | 2.35% | 2,750,149 | |
| 1,460,000 | Insider | 1.96% | 2,292,200 | |
| 666,403 | Institution | 0.89% | 1,046,253 | |
| 422,265 | Insider | 0.57% | 662,956 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,760,750 | Institution | 3.70% | 4,334,378 | |
| 666,403 | Institution | 0.89% | 1,046,253 | |
| 273,614 | Institution | 0.37% | 429,574 | |
| 152,298 | Institution | 0.20% | 239,108 | |
| 144,170 | Institution | 0.19% | 226,347 | |
| 78,659 | Institution | 0.11% | 123,495 | |
| 44,358 | Institution | 0.06% | 69,642 | |
| 40,000 | Institution | 0.05% | 62,800 | |
| 33,537 | Institution | 0.05% | 52,653 | |
| 28,203 | Institution | 0.04% | 44,279 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 2,228,292 | Institution | 2.99% | 3,609,833 | |
| 1,071,458 | Institution | 1.44% | 1,682,189 | |
| 472,664 | Institution | 0.63% | 742,082 | |
| 371,555 | Institution | 0.50% | 601,919 | |
| 288,578 | Institution | 0.39% | 467,496 | |
| 143,588 | Institution | 0.19% | 225,433 | |
| 63,977 | Institution | 0.09% | 100,444 | |
| 35,562 | Institution | 0.05% | 57,610 | |
| 27,723 | Institution | 0.04% | 41,862 | |
| 6,410 | Institution | <0.01% | 10,384 |
FAQ
Who Owns Inhibikase Therapeutics (IKT)?
According to the latest TipRanks data, approximately 60.31% of the company's stock is held by institutional investors, 9.88% is held by insiders, and 19.17% is held by retail investors.
What percentage of Inhibikase Therapeutics (IKT) stock is held by institutional investors?
According to the latest TipRanks data, approximately 60.31% of Inhibikase Therapeutics (IKT) stock is held by institutional investors.
What percentage of Inhibikase Therapeutics (IKT) stock is held by retail investors?
According to the latest TipRanks data, approximately 19.17% of Inhibikase Therapeutics (IKT) stock is held by retail investors.
Who owns the most shares of Inhibikase Therapeutics (IKT)?
Peter Harwin owns the most shares of Inhibikase Therapeutics (IKT).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.